Numen was founded by Luca Springer, Thomas Carroll in 2021.

Who are Numen's investors?

Numen's investors include Ankur Capital, Axilor Ventures, Tq Ventures Llc, Urban Innovation, Y Combinator.

Where is Numen headquartered?

Numen is headquartered in San Francisco, US.

Numen

YC S23

San Francisco, US · Founded 2021 · 18 employees · Hiring · 5 known investors

Find your way into Numen

Paths you didn't know you had: your email and LinkedIn already hold routes to the Numen team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Numen develops at-home cancer diagnostics and health data collection infrastructure using machine learning models to enable earlier intervention and improve patient outcomes.

Also known as Cleancard Inc. · Cleancard

AI & Machine Learning Biotech Digital Health Healthtech Medical Devices Machine Learning Healthcare Diagnostics AIUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S23)

Numen was founded in 2021 by Luca Springer and Thomas Carroll.

Luca Springer FounderLuca Springer holds master's degrees in computer science and global governance from Oxford University, where he was a Rhodes Scholar. He previously worked at Stockdale Street analyzing and investing in healthcare, consumer, and technology companies, and brings expertise in network science, computational game theory, and healthcare policy.

Thomas Carroll FounderThomas Carroll is a cancer researcher with expertise in bioinformatics, biomarkers, and methods development who is now building diagnostics at Numen.

Dominique PichéHead of Assay Development

Taylor Walmsley-EyreCTO

Alisa EmagScientist III

Micaela EverittSenior Scientist

Investors · 5

Ankur Capitallisted by Ankur CapitalMumbai · $500K – $2M

How we know: Ankur Capital's portfolio page · funding news · Not right? Tell us

Axilor Ventureslisted by Axilor VenturesBengaluru

How we know: Axilor Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Tq Ventures Llclisted by Tq Ventures LlcNew York

How we know: Tq Ventures Llc's portfolio page · Y Combinator's founder network · Not right? Tell us

Urban Innovationlisted by Urban InnovationSan Francisco · $500K – $3.5M

How we know: Urban Innovation's portfolio page · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Related companies · 7

Signatur BiosciencesSignatur Biosciences develops molecular diagnostic solutions using qPCR technology for in vitro diagnostics, targeting clinical and laboratory markets. The company aims to deliver advanced diagnostics on widely available instrumentation to expand access to cutting-edge healthcare globally.

GenomenonGenomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.

Yemaachi BiotechnologyYemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.

LeadIQLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.

UnimaUnima makes portable diagnostic tests that deliver disease identification at the point of care within 15 minutes at low cost, enabling rapid detection and monitoring of infectious diseases.

BiocartesianBiocartesian provides optical pooled screening services for functional genomics research. The company uses its proprietary ARADIA technology to link microscopy-based cellular phenotypes with genetic perturbations, enabling researchers to conduct large-scale CRISPR screens and other genomic studies with visual, spatial, and live-cell readouts.

IsablIsabl develops whole genome and transcriptome sequencing technology for cancer diagnosis, delivering comprehensive genomic profiling and treatment options to physicians and research teams. The company provides rapid cancer diagnostic tests in clinically relevant timeframes to improve outcomes for cancer patients globally.

Companies working in the same space as Numen.

Legal entities · 1

corporate structure

Cleancard Inc.

In the news

💧🧬Cleancard - Making cancer screening as easy as a pregnancy testycombinator.com · Aug 2023

Frequently asked questions

What does Numen do?: Numen develops at-home cancer diagnostics and health data collection infrastructure using machine learning models to enable earlier intervention and improve patient outcomes.
Who founded Numen?: Numen was founded by Luca Springer, Thomas Carroll in 2021.
Who are Numen's investors?: Numen's investors include Ankur Capital, Axilor Ventures, Tq Ventures Llc, Urban Innovation, Y Combinator.
Where is Numen headquartered?: Numen is headquartered in San Francisco, US.